156 related articles for article (PubMed ID: 35450057)
1. Identifying Mild Alzheimer's Disease With First 30-Min
Shen C; Wang Z; Chen H; Bai Y; Li X; Liang D; Liu X; Zheng H; Wang M; Yang Y; Wang H; Sun T
Front Aging Neurosci; 2022; 14():785495. PubMed ID: 35450057
[TBL] [Abstract][Full Text] [Related]
2. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.
Hatashita S; Yamasaki H; Suzuki Y; Tanaka K; Wakebe D; Hayakawa H
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):290-300. PubMed ID: 24085503
[TBL] [Abstract][Full Text] [Related]
3. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements.
McNamee RL; Yee SH; Price JC; Klunk WE; Rosario B; Weissfeld L; Ziolko S; Berginc M; Lopresti B; Dekosky S; Mathis CA
J Nucl Med; 2009 Mar; 50(3):348-55. PubMed ID: 19223409
[TBL] [Abstract][Full Text] [Related]
4. Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging.
Hatashita S; Yamasaki H
J Alzheimers Dis; 2010; 21(3):995-1003. PubMed ID: 20693641
[TBL] [Abstract][Full Text] [Related]
5. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease.
Ng S; Villemagne VL; Berlangieri S; Lee ST; Cherk M; Gong SJ; Ackermann U; Saunder T; Tochon-Danguy H; Jones G; Smith C; O'Keefe G; Masters CL; Rowe CC
J Nucl Med; 2007 Apr; 48(4):547-52. PubMed ID: 17401090
[TBL] [Abstract][Full Text] [Related]
6. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.
Lopresti BJ; Klunk WE; Mathis CA; Hoge JA; Ziolko SK; Lu X; Meltzer CC; Schimmel K; Tsopelas ND; DeKosky ST; Price JC
J Nucl Med; 2005 Dec; 46(12):1959-72. PubMed ID: 16330558
[TBL] [Abstract][Full Text] [Related]
7.
Chang Y; Li C; Yang H; Wu Y; Xu B; Zhang J; Wang R
Front Neurosci; 2020; 14():745. PubMed ID: 32848542
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Assessment of Amyloid-β Deposition by [18F]-Flutemetamol PET Imaging Compared With [11C]-PIB Across the Spectrum of Alzheimer's Disease.
Hatashita S; Wakebe D; Kikuchi Y; Ichijo A
Front Aging Neurosci; 2019; 11():251. PubMed ID: 31572167
[TBL] [Abstract][Full Text] [Related]
9. Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging.
Lopes Alves I; Heeman F; Collij LE; Salvadó G; Tolboom N; Vilor-Tejedor N; Markiewicz P; Yaqub M; Cash D; Mormino EC; Insel PS; Boellaard R; van Berckel BNM; Lammertsma AA; Barkhof F; Gispert JD
Alzheimers Res Ther; 2021 Apr; 13(1):82. PubMed ID: 33875021
[TBL] [Abstract][Full Text] [Related]
10. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
11. Cerebral Blood Flow and Aβ-Amyloid Estimates by WARM Analysis of [
Rodell AB; O'Keefe G; Rowe CC; Villemagne VL; Gjedde A
Front Aging Neurosci; 2016; 8():321. PubMed ID: 28123366
[No Abstract] [Full Text] [Related]
12. Simultaneous assessment of blood flow and myelin content in the brain white matter with dynamic [11 C]PiB PET: a test-retest study in healthy controls.
Yazdan-Panah A; Bodini B; Soulier T; Veronese M; Bottlaender M; Tonietto M; Stankoff B
EJNMMI Res; 2024 May; 14(1):50. PubMed ID: 38801594
[TBL] [Abstract][Full Text] [Related]
13. A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study.
Villemagne VL; Rowe CC; Barnham KJ; Cherny R; Woodward M; Bozinosvski S; Salvado O; Bourgeat P; Perez K; Fowler C; Rembach A; Maruff P; Ritchie C; Tanzi R; Masters CL
Alzheimers Dement (N Y); 2017 Nov; 3(4):622-635. PubMed ID: 29201996
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
Hatashita S; Wakebe D
J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
[TBL] [Abstract][Full Text] [Related]
15. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease.
Zhou Y; Resnick SM; Ye W; Fan H; Holt DP; Klunk WE; Mathis CA; Dannals R; Wong DF
Neuroimage; 2007 Jun; 36(2):298-312. PubMed ID: 17449282
[TBL] [Abstract][Full Text] [Related]
16. Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET.
Chen YJ; Rosario BL; Mowrey W; Laymon CM; Lu X; Lopez OL; Klunk WE; Lopresti BJ; Mathis CA; Price JC
J Nucl Med; 2015 Aug; 56(8):1199-205. PubMed ID: 26045309
[TBL] [Abstract][Full Text] [Related]
17. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
18. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy.
Whitwell JL; Ahlskog JE; Tosakulwong N; Senjem ML; Spychalla AJ; Petersen RC; Jack CR; Lowe VJ; Josephs KA
Parkinsonism Relat Disord; 2018 Mar; 48():3-9. PubMed ID: 29254665
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Utility of Integrated
Chang Y; Liu J; Wang L; Li X; Wang Z; Lin M; Jin W; Zhu M; Xu B
Front Aging Neurosci; 2021; 13():721780. PubMed ID: 34899265
[No Abstract] [Full Text] [Related]
20. Noninvasive Measurement of [
Okazawa H; Ikawa M; Tsujikawa T; Makino A; Mori T; Kiyono Y; Kosaka H
Diagnostics (Basel); 2020 Nov; 10(12):. PubMed ID: 33255169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
